SecBot SecBot
PRESS-RELEASE ·Filed Jul 20, 2026

TLX

Telix Pharmaceuticals Limited
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Revenue missed consensus by ~21%, but the miss is likely due to the consensus being stale or misaligned with quarterly cadence. The FY guidance of >$1B (including $40M Regeneron payment) implies H2 acceleration. Watch for FDA decisions on Pixclara (PDUFA Sept 11, 2026) and Zircaix BLA resubmission. The $600M convertible refinancing removes near-term debt overhang. The Regeneron deal provides non-dilutive capital and validates platform technology.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

TLX drug pipeline →

TLX591-Tx

● Neutral Named in this press release
Impact
Phase
Phase 3
Time to market
Likely 2028+ (Phase 3 Part 2 enrollment underway, followed by event-driven rPFS readout, then regulatory filing)
Next catalyst
None dated

What to watchWatch for enrollment completion updates on ProstACT Global Part 2 and any interim rPFS data. The stock is heavily influenced by Illuccix/Gozellix revenue execution, so TLX591-Tx is a pipeline upside option, not the core thesis today. Near-term catalysts center on Telix's imaging franchise (Pixclara PDUFA) rather than this therapeutic.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK AT ENTRY AT T+60
Entry
$10.92
T+0 close · Jul 20, 2026 · via day close
Latest settled
0.00%
T+60 · $10.92
Vs SPY
−3.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 21 $10.92entry
  2. T+1 · 4mo ago −5.49%α −5.38% · $10.32
  3. T+5 · 4mo ago −8.61%α −7.38% · $9.98
  4. T+20 · 3mo ago +8.79%α +6.23% · $11.88
  5. T+60 · 5w ago 0.00%α −3.97% · $10.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix reported Q2 2026 revenue of $247M, up 21% YoY and 7% QoQ, driven by Precision Medicine growth. The company expects FY 2026 revenue and other income to exceed $1B, tracking the upper end of guidance. R&D guidance was raised to $230-270M to accelerate pipeline programs, and a $600M convertible bond refinancing was completed.

Key Financial Metrics

Revenue
$247.0M
est $311.6M · -20.7% · +21.0% YoY
Guidance
$950M-$970M plus $40M non-refundable other income
maintained

Key Facts

  • Q2 2026 revenue $247M, up 21% YoY and 7% QoQ
  • Precision Medicine revenue $202M, up 30% YoY and 9% QoQ
  • FY 2026 revenue guidance tracking upper end of $950M-$970M, plus $40M non-refundable Regeneron payment
  • R&D expenditure guidance raised to $230M-$270M
  • Completed $600M convertible bond refinancing, extending maturities to 2031
  • FDA alignment on ProstACT Global Phase 3 trial for TLX591-Tx in mCRPC
  • Regeneron strategic collaboration for next-gen radiopharmaceutical therapies
  • Three new Non-Executive Directors appointed

Financial Impact

Q2 revenue $247M vs consensus $311.6M (miss), but FY guidance raised to >$1B including $40M Regeneron payment; R&D spend increased by $40-80M

revenuer&d expendituredebt maturity profile

Risk Factors

  • Revenue miss vs consensus may pressure near-term sentiment
  • R&D spend increase to $230-270M could pressure margins
  • Regulatory risk: FDA decisions on Pixclara, Zircaix, and TLX591-Tx IND
  • Convertible bond refinancing adds $600M debt, though at longer maturity

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3330166

Track record

27 reports on TLX

Performance horizon

10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (10h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026